Wellgistics Health Launches Brenzavvy Diabetes Drug Across 6,500-Pharmacy Network

Reuters

Dec 08

Wellgistics Health Launches Brenzavvy Diabetes Drug Across 6,500-Pharmacy Network

Wellgistics Health Inc. has announced the commercial launch of the diabetes prescription drug Brenzavvy® through its network of over 6,500 independent pharmacies, primarily serving rural communities in the United States. This expansion leverages Wellgistics' proprietary EinsteinRx™ artificial intelligence pharmacy platform and the blockchain-enabled PharmacyChain™ system to help pharmacists educate patients and providers about Brenzavvy's advantages over established SGLT-2 inhibitors like Jardiance®. The initiative aims to improve access and reduce out-of-pocket costs for the 33 million Americans with type II diabetes, while providing new revenue opportunities for pharmacists and supporting broader market access to Brenzavvy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115365) on December 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2589586653"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589586653\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589586653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589586653","market":"us","top_or_hot":-1,"title":"Wellgistics Health Launches Brenzavvy Diabetes Drug Across 6,500-Pharmacy Network","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Wellgistics Health Launches Brenzavvy Diabetes Drug Across 6,500-Pharmacy Network\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/WGRX\">Wellgistics Health Inc.</a> has announced the commercial launch of the diabetes prescription drug Brenzavvy® through its network of over 6,500 independent pharmacies, primarily serving rural communities in the United States. This expansion leverages Wellgistics' proprietary EinsteinRx™ artificial intelligence pharmacy platform and the blockchain-enabled PharmacyChain™ system to help pharmacists educate patients and providers about Brenzavvy's advantages over established SGLT-2 inhibitors like Jardiance®. The initiative aims to improve access and reduce out-of-pocket costs for the 33 million Americans with type II diabetes, while providing new revenue opportunities for pharmacists and supporting broader market access to Brenzavvy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115365) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wellgistics Health Launches Brenzavvy Diabetes Drug Across 6,500-Pharmacy Network</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWellgistics Health Launches Brenzavvy Diabetes Drug Across 6,500-Pharmacy Network\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 20:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Wellgistics Health Launches Brenzavvy Diabetes Drug Across 6,500-Pharmacy Network\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/WGRX\">Wellgistics Health Inc.</a> has announced the commercial launch of the diabetes prescription drug Brenzavvy® through its network of over 6,500 independent pharmacies, primarily serving rural communities in the United States. This expansion leverages Wellgistics' proprietary EinsteinRx™ artificial intelligence pharmacy platform and the blockchain-enabled PharmacyChain™ system to help pharmacists educate patients and providers about Brenzavvy's advantages over established SGLT-2 inhibitors like Jardiance®. The initiative aims to improve access and reduce out-of-pocket costs for the 33 million Americans with type II diabetes, while providing new revenue opportunities for pharmacists and supporting broader market access to Brenzavvy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115365) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4175","symbol_name":"保健护理产品经销商","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL4Yj5Db:1","article_id":"2589586653","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589586653","pubTimestamp":1765197612,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Wellgistics Health Inc. has announced the commercial launch of the diabetes prescription drug Brenzavvy through its network of over 6,500 independent pharmacies, primarily serving rural communities in the United States. This expansion leverages Wellgistics' proprietary EinsteinRx artificial intelligence pharmacy platform and the blockchain-enabled PharmacyChain system to help pharmacists educate patients and providers about Brenzavvy's advantages over established SGLT-2 inhibitors like Jardiance. The initiative aims to improve access and reduce out-of-pocket costs for the 33 million Americans with type II diabetes, while providing new revenue opportunities for pharmacists and supporting broader market access to Brenzavvy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4175":"保健护理产品经销商","WGRX":"Wellgistics Health Inc."},"translate_title":"Wellgistics Health在6,500家药房网络中推出Brenzavvy糖尿病药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGRX":0.9},"content_text":"Wellgistics Health Launches Brenzavvy Diabetes Drug Across 6,500-Pharmacy Network\n    \n\nWellgistics Health Inc. has announced the commercial launch of the diabetes prescription drug Brenzavvy® through its network of over 6,500 independent pharmacies, primarily serving rural communities in the United States. This expansion leverages Wellgistics' proprietary EinsteinRx™ artificial intelligence pharmacy platform and the blockchain-enabled PharmacyChain™ system to help pharmacists educate patients and providers about Brenzavvy's advantages over established SGLT-2 inhibitors like Jardiance®. The initiative aims to improve access and reduce out-of-pocket costs for the 33 million Americans with type II diabetes, while providing new revenue opportunities for pharmacists and supporting broader market access to Brenzavvy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115365) on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}